A Phase I Study of High-Dose Interleukin-2 With Sorafenib in Patients With Metastatic Renal Cell Carcinoma and Melanoma

This study was designed to evaluate the safety and feasibility of high-dose interleukin-2 (HD IL-2) followed by sorafenib in patients with metastatic melanoma (MM) and renal cell carcinoma (RCC). Biomarkers relevant to the antitumor effects of IL-2 that may be altered by sorafenib including the perc...

Descripción completa

Detalles Bibliográficos
Autores principales: Monk, Paul, Lam, Elaine, Mortazavi, Amir, Kendra, Kari, Lesinski, Gregory B., Mace, Thomas A., Geyer, Susan, Carson, William E., Tahiri, Sanaa, Bhinder, Arvinder, Clinton, Steven K., Olencki, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2014
Materias:
Clinical Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3966917/
https://www.ncbi.nlm.nih.gov/pubmed/24598448
http://dx.doi.org/10.1097/CJI.0000000000000023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3966917/
https://www.ncbi.nlm.nih.gov/pubmed/24598448
http://dx.doi.org/10.1097/CJI.0000000000000023

Ejemplares similares